Report
EUR 12.98 For Business Accounts Only

CHINA BIOLOGIC sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of CHINA BIOLOGIC (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date September 8, 2020, the closing price was USD 108.75 and its potential was estimated at USD 116.63.
Underlying
China Biologic Products Holdings Inc.

China Biologic Products is a biopharmaceutical company engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. Co.'s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). Human albumin is principally used to treat ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. IVIG products are primarily used to improve specific immunity, a defense mechanism by which the human body generates certain immunoglobulin, or antibodies, against invasion by potentially dangerous substances. All of Co.'s products are prescription medicines administered in the form of injections.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch